This promotional website has been developed, organised and funded by Boehringer Ingelheim.
Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Focus on: Ramadan
Prior to Ramadan, it is important to undertake medication reviews of your adult patients with type 2 diabetes who wish to fast during this time
Leaflet to share with your patients
Supporting your patients during Ramadan
Developed by Alia Gilani,
Senior Diabetes Clinical Pharmacist,
Primary Care Sheffield, Sheffield
Alia is a part-time Senior Diabetes Clinical Pharmacist for Primary Care Sheffield, whose interests lie in ethnic inequalities and diabetes. She helped to establish and run a bilingual medication review service in NHS Glasgow in 2002 and received local and national awards for this work. She has chaired the NHS Glasgow Diabetes Ethnicity and Inequalities Group in the past.
Alia has been running outreach clinics for South Asian people with diabetes for over a decade and was a member of the Diabetes Working Group for the South Asian Health Foundation (SAHF) for 13 years and had the role of Regional Lead and Chief Executive Officer for 2 years. She was the first pharmacist on the Primary Care Diabetes Society (PCDS) and a committee member for 7 years.
Healthcare professional resources
The risks of fasting during Ramadan in adults with type 2 diabetes
Supporting your patients during Ramadan
Reference: Salti I et al. Diabetes Care 2004;27:2306–11
Watch the most recent webinar
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by OmniaMed Communications.
PC-GB-106628 V6 | December 2024
PC-GB-110742 | December 2024
Copyright 2024 Oxbridge Solutions Limited®, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.
Quick questionnaire